In this study, we demonstrated that Trop-2, the target protein of sacituzumab govitecan, was widely expressed in UTUC and that its high expression was associated with a better prognosis. This evidence concerns the gene TACSTD2 and renal pelvis/ureter urothelial carcinoma.